JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in blockbuster-level sales down the line.